A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

which is similar to the inflammatory processes seen in asthma and eosinophilic rhinosinusitis. This has led to a reevaluation of the diagnostic criteria and treatment approaches for EOM ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Around 50% of asthma attacks and 30% of COPD attacks are "eosinophilic exacerbations ... The group taking prednisolone alone had a 74% treatment failure rate at 30 days, reducing to 45% ...

Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanizedmonoclonal antibody that simultaneously blocks the ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 24 January ...

Intermediate group 2 innate lymphoid cells (ILC2s) appear to be able to get around cutting-edge asthma treatments by ...

Targeted biologic drugs have revolutionized the treatment of severe asthma driven ... should ask their doctor if they might have eosinophilic asthma. Every Exponent article goes through checks ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Although cost-related asthma treatment nonadherence has declined in the US, nearly 1 in 6 patients are still nonadherent due to cost concerns.

A simple, noninvasive nasal swab identified a predominance of T2-low asthma subtypes in racial and ethnic minority pediatric ...